

Claims:

1. Use of an anti-FcRn antibody for the manufacture of a medicament for the treatment of myasthenia gravis (MG) in a subject, wherein six doses of the antibody are to be administered weekly, wherein each dose is 7mg/kg or 10mg/kg, wherein the antibody is to be administered subcutaneously, and wherein the antibody has a heavy chain comprising the sequence given in SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.
5
2. The use according to claim 1 wherein the antibody is provided as a pharmaceutical composition comprising one or more of a pharmaceutically acceptable excipient, diluent or carrier.
10
3. The use according to claim 2 wherein the pharmaceutical composition further comprises one or more other active ingredients.
4. The use according to any one of claims 1 to 3 wherein the six weekly doses are to be administered followed by one or more additional doses that are lower and/or less frequent than the initial six doses.
15
5. The use according to any one of claims 1 to 4 wherein the subject is suffering from generalised MG which is classified as moderate to severe.
6. The use according to any one of claims 1 to 5 wherein the subject is anti-AChR or anti-MuSK autoantibody-positive and optionally is being considered for treatment with IVIg or plasma exchange.
20